CL2021000152A1 - Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 - Google Patents

Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1

Info

Publication number
CL2021000152A1
CL2021000152A1 CL2021000152A CL2021000152A CL2021000152A1 CL 2021000152 A1 CL2021000152 A1 CL 2021000152A1 CL 2021000152 A CL2021000152 A CL 2021000152A CL 2021000152 A CL2021000152 A CL 2021000152A CL 2021000152 A1 CL2021000152 A1 CL 2021000152A1
Authority
CL
Chile
Prior art keywords
interleukin
inhibitors
activity
sulfonylurea compounds
nlrp3
Prior art date
Application number
CL2021000152A
Other languages
English (en)
Spanish (es)
Inventor
Matthew Volgraf
Craig Stivala
Jeffrey A Stafford
James M Veal
Lynnie Lin Trzoss
Christopher Mcbride
Richard M Pastor
Steven Thomas Staben
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2021000152A1 publication Critical patent/CL2021000152A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CL2021000152A 2018-07-20 2021-01-19 Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 CL2021000152A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862701358P 2018-07-20 2018-07-20

Publications (1)

Publication Number Publication Date
CL2021000152A1 true CL2021000152A1 (es) 2021-07-09

Family

ID=67515207

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000152A CL2021000152A1 (es) 2018-07-20 2021-01-19 Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1

Country Status (20)

Country Link
US (1) US11560391B2 (cg-RX-API-DMAC7.html)
EP (1) EP3823726A1 (cg-RX-API-DMAC7.html)
JP (1) JP7411631B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210034588A (cg-RX-API-DMAC7.html)
CN (1) CN112437683A (cg-RX-API-DMAC7.html)
AR (1) AR117617A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019305095A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021001012A2 (cg-RX-API-DMAC7.html)
CA (1) CA3104199A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000152A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021000817A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210024A (cg-RX-API-DMAC7.html)
IL (1) IL280139A (cg-RX-API-DMAC7.html)
MA (1) MA53170A (cg-RX-API-DMAC7.html)
MX (1) MX2021000660A (cg-RX-API-DMAC7.html)
PE (1) PE20211049A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020552155A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202012159TA (cg-RX-API-DMAC7.html)
TW (1) TW202019937A (cg-RX-API-DMAC7.html)
WO (1) WO2020018970A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12617802B2 (en) 2020-01-22 2026-05-05 Genentech, Inc. Sulfonimidamide compounds as NLRP3 modulators

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA126675C2 (uk) 2017-01-23 2023-01-11 Дженентек, Інк. Хімічні сполуки як інгібітори активності інтерлейкіну-1
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
CN114008030A (zh) 2019-06-21 2022-02-01 Ac免疫有限公司 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪
CA3158123A1 (en) * 2019-11-12 2021-05-20 Yonggang Wei Amide derivative and preparation method therefore and use thereof in medicine
US12624010B2 (en) 2020-06-19 2026-05-12 Ac Immune Sa Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway
JP2025502732A (ja) 2021-12-22 2025-01-28 エーシー・イミューン・エス・アー ジヒドロオキサゾール誘導体化合物
CA3252822A1 (en) 2022-02-21 2023-08-24 Viva Star Biosciences (Suzhou) Co., Ltd. NOVEL BICYCLIC SUBSTITUTED SULFONYLUREA COMPOUNDS AS INTERLEUKIN-1 ACTIVITY INHIBITORS
JP2025524640A (ja) 2022-07-14 2025-07-30 エーシー・イミューン・エス・アー Nlrp3インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
WO2024023266A1 (en) 2022-07-28 2024-02-01 Ac Immune Sa Novel compounds
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法
CN122555708A (zh) 2024-01-17 2026-08-11 Ac免疫有限公司 用作nlrp3炎症小体通路抑制剂的咪唑并[1,2-d][1,2,4]三嗪衍生物
CN122555707A (zh) 2024-01-17 2026-08-11 Ac免疫有限公司 用作nlrp3炎症小体通路抑制剂的咪唑并[1,2-d][1,2,4]三嗪衍生物
WO2025163069A1 (en) 2024-01-31 2025-08-07 Ac Immune Sa Novel compounds
WO2026132518A1 (en) 2024-12-20 2026-06-25 Ac Immune Sa Heterocyclic compounds modulating the nlrp3 inflammasome pathway

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216026A (en) 1990-07-17 1993-06-01 Eli Lilly And Company Antitumor compositions and methods of treatment
DK1270565T3 (da) 1997-01-29 2004-10-04 Pfizer 4-substitueret furan-2-sulfonamid og dets anvendelse i fremstillingen af sulfonylurinstofderivater
BR0014003A (pt) 1999-09-14 2002-05-21 Pfizer Prod Inc Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
AU2002341321A1 (en) 2001-11-30 2003-06-10 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
CA2789665C (en) * 2010-02-22 2020-06-16 Askat Inc. Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
TW201311693A (zh) 2011-09-02 2013-03-16 Kyowa Hakko Kirin Co Ltd 化學激活激素受體活性調節劑
JP6929792B2 (ja) 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
BR112018016671A2 (pt) 2016-02-16 2018-12-26 The University Of Queensland sulfonilureias e compostos relacionados e uso do mesmo
MA44729A (fr) 2016-04-18 2021-05-12 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
US11447460B2 (en) 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
UA126675C2 (uk) 2017-01-23 2023-01-11 Дженентек, Інк. Хімічні сполуки як інгібітори активності інтерлейкіну-1
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
EP3649112A1 (en) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
CN110914256A (zh) 2017-07-07 2020-03-24 英夫拉索姆有限公司 新颖磺酰胺羧酰胺化合物
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
EP3668862A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019034697A1 (en) 2017-08-15 2019-02-21 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
AU2018317800A1 (en) 2017-08-15 2020-02-13 Inflazome Limited Novel sulfonamide carboxamide compounds
TW201910314A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019092172A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
GB201803393D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
GB201803394D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
JP2021529780A (ja) 2018-07-03 2021-11-04 ノバルティス アーゲー Nlrp3アンタゴニストを使用するtnf阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法
JP2021529187A (ja) 2018-07-03 2021-10-28 ノバルティス アーゲー Nlrpモジュレータ
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
AR117951A1 (es) 2018-07-20 2021-09-08 Gruenenthal Gmbh Derivados de triazolquinoxalina adicionalmente sustituidos
SG11202101480XA (en) 2018-08-15 2021-03-30 Inflazome Ltd Novel sulfonamideurea compounds
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
US20230011652A1 (en) 2018-10-24 2023-01-12 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
GB201819083D0 (en) 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
US20220227707A1 (en) 2019-01-22 2022-07-21 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
WO2021002887A1 (en) 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Gut-targeted nlrp3 antagonists and their use in therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12617802B2 (en) 2020-01-22 2026-05-05 Genentech, Inc. Sulfonimidamide compounds as NLRP3 modulators

Also Published As

Publication number Publication date
IL280139A (en) 2021-03-01
EP3823726A1 (en) 2021-05-26
SG11202012159TA (en) 2021-01-28
CR20210024A (es) 2021-02-22
CA3104199A1 (en) 2020-01-23
BR112021001012A2 (pt) 2021-04-20
CO2021000817A2 (es) 2021-02-17
US20210261568A1 (en) 2021-08-26
KR20210034588A (ko) 2021-03-30
PE20211049A1 (es) 2021-06-04
JP7411631B2 (ja) 2024-01-11
AU2019305095A1 (en) 2020-12-17
US11560391B2 (en) 2023-01-24
TW202019937A (zh) 2020-06-01
PH12020552155A1 (en) 2021-07-05
AR117617A1 (es) 2021-08-18
JP2021530536A (ja) 2021-11-11
MX2021000660A (es) 2021-03-25
WO2020018970A1 (en) 2020-01-23
MA53170A (fr) 2021-05-26
CN112437683A (zh) 2021-03-02

Similar Documents

Publication Publication Date Title
CO2021000817A2 (es) Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1
CO2021001530A2 (es) Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1
CO2019009036A2 (es) Compuestos químicos como inhibidores de la actividad de la interleuquina-1
MX2022000711A (es) Inhibidores de parp1.
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
MX2018005925A (es) Purinonas como inhibidores de proteasa específica de ubiquitina 1.
CL2019001709A1 (es) Derivados pirazol como inhibidores de malt1.
MX2020002963A (es) Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 especifica de ubiquitina.
MX2022003166A (es) Moduladores de il-17a y usos de los mismos.
MX2019011825A (es) Tratamiento de enfermedades inflamatorias con inhibidores de actividad de c5a.
ECSP20018487A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CL2015002194A1 (es) Inhbidores de erk y sus usos
MX387984B (es) Inhibidor del egfr y preparación y aplicación del mismo.
MX2020004724A (es) Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MA40076A (fr) Inhibiteurs de syk
CL2022003348A1 (es) Composiciones y métodos para el tratamiento del síndrome de dificultad respiratoria aguda y trastornos inflamatorios
MX2020003192A (es) Terapia de combinacion usando un antagonista del receptor de quimiocina tipo 2 (ccr2) y un inhibidor de pd-1/pd-l1.
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
CU20200041A7 (es) Amidas de imidazopiridina sustituidas
MX2019010554A (es) Pirimidopirimidinonas utiles como inhibidores de la quinasa wee-1.
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
CL2019001397A1 (es) Estabilidad mejorada de composiciones que contienen inhibidor de la ureasa.
EA201792346A1 (ru) ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ, sGC АКТИВАТОРОВ, ОТДЕЛЬНО И В КОМБИНАЦИЯХ С PDE5 ИНГИБИТОРАМИ, ДЛЯ ЛЕЧЕНИЯ ПАЛЬЦЕВИДНЫХ ЯЗВ (DU), СОПУТСТВУЮЩИХ СИСТЕМНОМУ СКЛЕРОЗУ (SSc)